A nanocellulose-enabled surface for predictive 3D cell culture
Cell2Bio AB is advancing cell culture through a proprietary, patent-pending surface platform based on nanocellulose. The technology was discovered at SciLifeLab and developed at KTH: cells seeded onto the surface self-assemble into uniform 3D spheroids that better mimic natural tissue architecture than conventional 2D cultures.
3D spheroid formation
Cells form dense, uniform spheroids even from low seeding densities, mimicking natural tissue architecture.
Simple handling
Spheroids remain securely attached during washing, media exchange, and transfer between workflows.
High-throughput ready
Compatible with standard 96-well plates, incubators, imagers, and liquid handlers for screening.
Scalable production
Three independent production batches and 12-month stability demonstrated for the C2B 3D plate.
Broad compatibility
Supports multiple cell types, co-cultures, patient-derived tumoroids, and organoid transitions.
Protected IP
Patent-pending surface platform with a strategy to extend into organoid-on-chip and tumor-on-chip products.
From surface activation to readout
Our coating is produced through a controlled surface-activation and self-assembly process. The resulting nanocellulose layer provides the right mechanical and biochemical cues for cells to aggregate, proliferate, and mature into dense spheroids — while remaining compatible with standard imaging, washing, and retrieval workflows.
- Nanocellulose surface engineered for optimal cell attachment and aggregation
- No specialized equipment required — works with standard lab infrastructure
- Supports co-culture and complex model development
- Compatible with imaging, staining, and endpoint readouts
- Scalable from research assays to screening formats
One platform, many applications
The same surface technology powers a growing set of workflows: high-throughput drug screening, patient-derived tumoroids, multicellular spheroids, spheroid-to-organoid transition, microfluidic and organ-on-chip integration, toxicity testing, and synthetic-biology screening.
- High-throughput drug screening
- Patient-derived tumoroids for personalized medicine
- Multicellular spheroids with immune or stromal cells
- Spheroid-to-organoid transition platform
- Microfluidic and organ-on-chip integration
- Spheroid-based toxicity testing
- Synthetic biology and gene-therapy testing
Why surface-based 3D growth?
Traditional 3D methods often force a trade-off between biological relevance and handling convenience. Cell2Bio's surface-based approach combines both: cells form true spheroids while the plate remains easy to wash, image, and automate — delivering the reproducibility and scalability required for modern drug discovery.